Merrimack Pharmaceuticals Inc (NASDAQ:MACK) announced its third quarter 2016 financial results. Merrimack will host a live conference call and webcast today, Wednesday, November …
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) announced that the U.S.
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) announced final results from the pivotal Phase 3 NAPOLI-1 study validating the use of ONIVYDE® (irinotecan liposome injection) in combination …
Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) announced a major corporate restructuring with the objective of prioritizing its research and development on a focused set of systems …
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) shares shot up nearly 21% yesterday on back of August’s strong script data for ONIVYDE, the first approved anti-cancer treatment, …
Merrimack Pharmaceuticals Inc’s (NASDAQ:MACK) leading pipeline drug, ONIVYDE, an irinotecan liposome injection designed to treat patients suffering from metastatic pancreatic cancer, recently underperformed …
Baird analyst Michael Ulz gave his two cents on Merrimack Pharmaceuticals Inc (NASDAQ:MACK), following the company’s second-quarter earnings report. MACK saw Onivyde, its first …
Merrimack Pharmaceuticals Inc Merrimack Pharmaceuticals Inc (NASDAQ:MACK) shares closed down over 6% Friday, after the cancer drug maker reported second-quarter results, with net Onivyde sales …
In a research report issued Friday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Merrimack Pharmaceuticals Inc (NASDAQ:MACK), and reduced …
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) shares are down over 8% this morning, after the cancer drug maker reported second-quarter results, with net Onivyde sales of …
